Bristol-Myers Squibb Company Ce (CELG-RI) Comparison with companies in other sectors?

Bristol-Myers Squibb Company Ce has a share price of 3.31T. You can analyze Bristol-Myers Squibb Company Ce (CELG-RI) competitors across different market sectors through stock heatmaps.

What are CELG-RI's NET and operating margins?

Bristol-Myers Squibb Company Ce (CELG-RI) operating margin is around 0.18, and net profit margin is approximately 0.11 as of the latest reports.

In what way does CELG-RI's earnings per share (EPS) trend reflect its financial momentum?

Bristol-Myers Squibb Company Ce (CELG-RI) EPS is N/A (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Bristol-Myers Squibb Company Ce is N/A, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Bristol-Myers Squibb Company Ce?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Bristol-Myers Squibb Company Ce like P/E which is 18.10, P/B which is 5.64, and PEG which is 0.11. Compare them with sector averages to evaluate if the stock is priced fairly.

Bristol-Myers Squibb Company Ce

CELG-RI•NYSE

Healthcare

Drug Manufacturers - General

$0.03

$0.00(0.34%)

Fundamental Analysis of Bristol-Myers Squibb Company Ce (CELG-RI)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

P/E Ratio

ROE

0.32%

Net Margin

0.11%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$100.01B

Shares OutstandingTotal number of shares issued

$3.31T

Book Value/ShareNet worth per share

$8.59

Revenue/ShareAnnual revenue per share

$23.45

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

Net MarginNet income as percentage of revenue

11.38%

Operating MarginOperating income as percentage of revenue

18.45%

ROEReturn on shareholders' equity

31.93%

ROAReturn on total assets

5.86%

ROCEReturn on capital employed

12.85%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$6.44

Cash/ShareCash and equivalents per share

$5.80

FCF YieldFree cash flow as percentage of market cap

13.29%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$2.46

Dividend YieldAnnual dividend as percentage of stock price

5.08%

Financial Ratios Analysis data is not available for CELG-RIFinancial Ratios Analysis details for CELG-RI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for CELG-RISector Benchmarking details for CELG-RI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Bristol-Myers Squibb Company Ce Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Bristol-Myers Squibb Company Ce. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Bristol-Myers Squibb Company Ce's unique business strengths and challenges.

Key Financial Metrics for Bristol-Myers Squibb Company Ce

For Bristol-Myers Squibb Company Ce, essential financial indicators include EPS -, PE -, and ROE 0.32. These key ratios reveal insights into Bristol-Myers Squibb Company Ce's profitability, valuation, and operational health. Understanding these metrics enables you to compare Bristol-Myers Squibb Company Ce with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Bristol-Myers Squibb Company Ce

Metrics like Net Margin 11.38% and ROA 5.86% shed light on how well Bristol-Myers Squibb Company Ce is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Bristol-Myers Squibb Company Ce can sustain its operations and continue growing in the future.

Valuation and Market Position of Bristol-Myers Squibb Company Ce

Using ratios such as P/B Ratio 5.64 and PEG Ratio 0.11, investors can assess whether Bristol-Myers Squibb Company Ce is appropriately valued based on its financials and growth potential. These figures, combined with Bristol-Myers Squibb Company Ce's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Bristol-Myers Squibb Company Ce

Financial health indicators, such as Debt/Equity Ratio 2.95 and Cash Flow $6.44, provide a snapshot of Bristol-Myers Squibb Company Ce's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Bristol-Myers Squibb Company Ce, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Bristol-Myers Squibb Company Ce

Investing in Bristol-Myers Squibb Company Ce based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Bristol-Myers Squibb Company Ce focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;